Basic Stats
| CIK | 1600847 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Gamida Cell Ltd.
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| May 24, 2024 |
IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE Exhibit 99.4 EXHIBIT A IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE In re: GAMIDA CELL INC. Debtor. ) ) ) ) ) ) ) Chapter 11 Case No. 24-11003 (JKS) AMENDED PREPACKAGED CHAPTER 11 PLAN OF REORGANIZATION OF GAMIDA CELL INC. Stanley B. Tarr (DE Bar No. 5535) BLANK ROME LLP 1201 N. Market Street, Suite 800 Wilmington, Delaware 19801 Michael Klein Evan Lazerowitz COOLEY LLP 55 Hu |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-38716 Gamida Cell Ltd. (Exact name of registrant as specified in its cha |
|
| May 24, 2024 |
IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE Exhibit 99.1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE In re: Gamida Cell Ltd.1 Debtor in a Foreign Proceeding. Chapter 15 Case No. 24-10847 (JKS) Re. Docket Nos. 4, 5, 6, 22, 28, 37, 38, 39 FINAL ORDER GRANTING RECOGNITION AND RELIEF IN AID OF A FOREIGN MAIN PROCEEDING Upon a hearing having been held before this Court on May15, 2024 (the “Hearing”) to consider the Verifie |
|
| May 24, 2024 |
IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE Exhibit 99.2 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE In re: Gamida Cell Ltd.1 Debtor in a Foreign Proceeding. Chapter 15 Case No. 24-11003 (JKS) Re. Docket Nos. 5, 6, 22, 29, 37, 38, and 40 FINAL ORDER GRANTING MOTION (I) RECOGNIZING AND ENFORCING THE DEBT ARRANGEMENT AND ISRAELI CONFIRMATION ORDER PURSUANT TO 11 U.S.C. §§ 105(a), 1145, 1507(a), 1521, AND 1525(A), AND (I |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2024 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 24, 2024 |
IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE Exhibit 99.3 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE In re: GAMIDA CELL INC.,1 Debtor. Chapter 11 Case No. 24-11003 (JKS) Re: Docket Nos. 4, 5, 60 ORDER (I) APPROVING THE DISCLOSURE STATEMENT FOR, AND CONFIRMING, THE PREPACKAGED CHAPTER 11 PLAN OF REORGANIZATION OF GAMIDA CELL INC., AND (II) GRANTING RELATED RELIEF The above-captioned debtor and debtor in possession (the |
|
| May 24, 2024 |
CONTINGENT VALUE RIGHTS AGREEMENT Exhibit 10.1 CONTINGENT VALUE RIGHTS AGREEMENT This CONTINGENT VALUE RIGHTS AGREEMENT, dated as of May 24, 2024 (this “Agreement”), is entered into by and between Ayrmid Ltd., a company incorporated under the laws of England and Wales (the “Company”), and Broadridge Corporate Issuer Solutions, LLC, a Pennsylvania limited liability company, as rights agent (the “Rights Agent”). RECITALS WHEREAS, on |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38716 GAMIDA CELL LTD. |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ For the Transition Per |
|
| May 10, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 4) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2024 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporatio |
|
| May 10, 2024 |
Exhibit 99.1 [Emblem:] Israel The Be’er Sheva District Court Insolvency Proceeding 63461-03-24 Gamida Cell Ltd. v. The Commissioner of Insolvency et al. Before: The Honorable Judge Ya’akov Persky In the Matter of: The Insolvency and Financial Rehabilitation Law, 5778-2018 (Hereinafter: the “Law”) And in the Matter of: Gamida Cell, Ltd. Via its counsel, Pinni Yaniv, Adv., and Merav Ben-Artzi Halper |
|
| May 9, 2024 |
As filed with the Securities and Exchange Commission on May 9, 2024 As filed with the Securities and Exchange Commission on May 9, 2024 Registration No. |
|
| May 9, 2024 |
As filed with the Securities and Exchange Commission on May 9, 2024 As filed with the Securities and Exchange Commission on May 9, 2024 Registration No. |
|
| May 9, 2024 |
As filed with the Securities and Exchange Commission on May 9, 2024 As filed with the Securities and Exchange Commission on May 9, 2024 Registration No. |
|
| May 9, 2024 |
As filed with the Securities and Exchange Commission on May 9, 2024 As filed with the Securities and Exchange Commission on May 9, 2024 Registration No. |
|
| May 9, 2024 |
As filed with the Securities and Exchange Commission on May 9, 2024 As filed with the Securities and Exchange Commission on May 9, 2024 Registration No. |
|
| May 9, 2024 |
As filed with the Securities and Exchange Commission on May 9, 2024 As filed with the Securities and Exchange Commission on May 9, 2024 Registration No. |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2024 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission File |
|
| April 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 3) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2024 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporatio |
|
| April 11, 2024 |
Exhibit 99.1 Court of Law In the Be’er Sheva District Court Before the Honorable Judge Yaakov Persky Insolvency Case 63461-03-24 Discussion date: 04 April 2024 Re: Insolvency and Financial Rehabilitation Law 5778-2018 (hereinafter: “the Law”) And re: Insolvency and Financial Rehabilitation Regulations, 5779-2019 (hereinafter: “the Regulations”) Re: Gamida Cell Ltd., P.C. 512601204 (hereinafter: “t |
|
| April 5, 2024 |
Exhibit 99.1 Gamida Cell ltd. and its subsidiary CONSOLIDATED FINANCIAL STATEMENTS AS OF DECEMBER 31, 2022 U.S. DOLLARS IN THOUSANDS INDEX Page Report of Independent Registered Public Accounting Firm (PCAOB ID: #1281) F-2 Consolidated Balance Sheets F-3 – F-4 Consolidated Statements of Operations F-5 Consolidated Statements of Changes in Shareholders’ Equity (Deficit) F-6 Consolidated Statements o |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 2) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2024 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporatio |
|
| March 29, 2024 |
Exhibit 99.1 Translated from the Hebrew Legaltrans 14 Adar 5784, March 27, 2024 File No. 63461-03-24 Judge Y. Persky Decision An urgent hearing is hereby scheduled for next Thursday, April 4, 2024 at 11:00 a.m. Counsel for the Petitioner are requested to serve a copy of the motion and this decision on the Commissioner by personal delivery within 24 hours. Counsel for the Petitioner are requested t |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2024 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporatio |
|
| March 27, 2024 |
2017 Share Incentive Plan, as amended Exhibit 10.6 Gamida Cell Ltd. 2017 Share Incentive Planr (as amended and restated November 17, 2021) Unless otherwise defined, terms used herein shall have the meaning ascribed to them in Section 2 hereof. 1. PURPOSE; TYPES OF AWARDS; CONSTRUCTION. 1.1. Purpose. The purpose of this 2017 Share Incentive Plan (as amended, this “Plan”) is to afford an incentive to Service Providers of Gamida Cell Ltd |
|
| March 27, 2024 |
Gamida Cell Ltd. Incentive Compensation Recoupment Policy Exhibit 97.1 Gamida Cell Ltd. Incentive Compensation Recoupment Policy 1. Introduction The Compensation and Talent Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Gamida Cell Ltd., a corporation organized under the laws of Israel (the “Company”), has determined that it is in the best interests of the Company and its shareholders to adopt this Incentive Compensat |
|
| March 27, 2024 |
Exhibit 10.15 AMENDED & RESTATED EMPLOYMENT AGREEMENT This AMENDED & RESTATED EMPLOYMENT AGREEMENT (this “Agreement”), dated as of March 12, 2024 (the “Effective Date”) is by and between GAMIDA CELL INC., a Delaware Corporation (the “Company”), and ABIGAIL JENKINS (the “Employee”) (each a “Party” and collectively, the “Parties”). WHEREAS, Employee is employed by the Company and performs services f |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2024 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission File |
|
| March 27, 2024 |
Gamida Cell Ltd. Amended and Restated Compensation Policy Exhibit 10.7 COMPENSATION POLICY GAMIDA CELL LTD. Compensation Policy for Executive Officers and Directors (As Adopted by the Shareholders on October 19, 2023) Page A. Overview and Objectives 1 B. Base Salary and Benefits 3 C. Cash Bonuses 5 D. Equity Based Compensation 7 E. Retirement and Termination of Service Arrangements 8 F. Exculpation, Indemnification and Insurance 9 G. Arrangements upon Ch |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-38716 GAMIDA CELL LTD. (Exact |
|
| March 27, 2024 |
Exhibit 4.1 DESCRIPTION OF SHARE CAPITAL The following descriptions of our share capital and provisions of our amended and restated articles of association are summaries and do not purport to be complete. For a complete description you should refer to our amended and restated articles of incorporation which are included as an exhibit to our Annual Report on Form 10-K, and to the applicable provisi |
|
| March 27, 2024 |
Exhibit 99.1 Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update Company announces commencement of restructuring process supported by Highbridge Capital Management Continued progress of launch of Omisirge® (omidubicel-onlv), with the delivery of six units in 2023, as well as significant transplant center onboarding Company to host conference call tod |
|
| March 27, 2024 |
Exhibit 10.16 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”), dated as of March 12, 2024 (the “Effective Date”) is by and between GAMIDA CELL, INC., a Delaware Corporation (the “Company”), and MICHELE KORFIN (the “Employee”) (individually, each a “Party” and collectively, the “Parties”). WHEREAS, Employee is employed by the Company and p |
|
| March 27, 2024 |
Exhibit 10.1 THIS RESTRUCTURING SUPPORT AGREEMENT AND THE DOCUMENTS ATTACHED HERETO COLLECTIVELY DESCRIBE A PROPOSED RESTRUCTURING OF THE COMPANY PARTIES THAT WILL BE EFFECTUATED THROUGH PART X TO THE ISRAELI INSOLVENCY AND FINANCIAL REHABILITATION LAW, 2018 IN THE STATE OF ISRAEL, A CHAPTER 15 CASE IN THE BANKRUPTCY COURT AND, AS NECESSARY, ANY ADDITIONAL LIQUIDATION, INSOLVENCY OR RESTRUCTURING |
|
| March 27, 2024 |
Exhibit 10.24 SECOND AMENDED & RESTATED CONSULTING AGREEMENT THIS SECOND AMENDED & RESTATED CONSULTING AGREEMENT (the “Agreement”) is entered into as of December 31, 2023 (the “Effective Date”) by and between Gamida Cell Ltd., whose address is at 5 Nahum Heftsadie St., Jerusalem, Israel 9548401 (the “Company”), and Terry Coelho, an individual (the “Consultant”). WHEREAS, Company is in the business |
|
| March 27, 2024 |
Exhibit 10.18 AMENDED AND RESTATED AMENDMENT TO EMPLOYMENT AGREEMENT This AMENDED AND RESTATED AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into as of March 14, 2024, by and between Gamida Cell Inc., a Delaware corporation (the “Company”), and Ronit Simantov (the “Employee”) (individually, each a “Party” and collectively, the “Parties”). WHEREAS, Employee is employed by |
|
| March 27, 2024 |
Exhibit 99.2 Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management Company expected to receive significant new capital from Highbridge to bolster the commercialization of allogeneic stem cell transplant Omisirge® (omidubicel-onlv) Gamida Cell to become a private company under ownership of Highbridge following Israeli court approval BOSTON & NEW YORK |
|
| March 27, 2024 |
Exhibit 10.17 AMENDED AND RESTATED AMENDMENT TO EMPLOYMENT AGREEMENT This AMENDED AND RESTATED AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into as of March 12, 2024, by and between Gamida Cell Inc., a Delaware corporation (the “Company”), and Joshua Patterson (the “Employee”) (individually, each a “Party” and collectively, the “Parties”). WHEREAS, Employee is employed |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission File |
|
| February 14, 2024 |
GMDA / Gamida Cell Ltd. / Rock Springs Capital Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2024 |
GMDA / Gamida Cell Ltd. / CVI Investments, Inc. - SC 13G/A Passive Investment CUSIP No: M47364100 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* Gamida Cell Ltd. (Name of Issuer) Ordinary shares, NIS 0.01 par value per share (Title of Class of Securities) M47364100 (CUSIP Number |
|
| February 13, 2024 |
GMDA / Gamida Cell Ltd. / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Gamida Cell Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M47364100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| February 2, 2024 |
GMDA / Gamida Cell Ltd. / HIGHBRIDGE CAPITAL MANAGEMENT LLC Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Gamida Cell Ltd. (Name of Issuer) Ordinary shares, par value NIS 0.01 per share (Title of Class of Securities) M47364100 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant |
|
| January 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2024 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission Fil |
|
| January 29, 2024 |
Gamida Cell Actively Pursuing Strategic Alternatives Exhibit 99.1 Media Contact: Dan Boyle Orangefiery [email protected] 1-818-209-1692 Investor Contact: Chuck Padala LifeSci Advisors [email protected] 1-646-627-8390 Gamida Cell Actively Pursuing Strategic Alternatives BOSTON — JANUARY 29, 2024 — Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced it is actively pursui |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission File |
|
| December 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission Fi |
|
| December 13, 2023 |
December 13, 2023 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Joseph McCann Jimmy McNamara Re: Gamida Cell Ltd. Amendment No. 1 to Registration Statement on Form S-3 Filed December 6, 2023 File No. 333-275579 Acceleration Request Requested Date: December 14, 2023 Requested Time: 4:00 p.m. Eastern Time Ladies and |
|
| December 6, 2023 |
As filed with the Securities and Exchange Commission on December 6, 2023 As filed with the Securities and Exchange Commission on December 6, 2023 Registration No. |
|
| November 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2023 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 20, 2023 |
GMDA / Gamida Cell Ltd / Ai Gamida Holdings Llc - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 9)* Gamida Cell Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M47364100 (CUSIP Number) Alejandro Moreno Langhorne S. Perrow c/o Access Industries, Inc. 40 West 57th Street, 28th Floor New York, Ne |
|
| November 20, 2023 |
EX-99.14 Exhibit 99.14 Joint Filing Agreement The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended. Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contai |
|
| November 15, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) GAMIDA CELL LTD. |
|
| November 15, 2023 |
Exhibit 4.2 GAMIDA CELL LTD., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [·], 20 Debt Securities Table Of Contents Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 Section 2. |
|
| November 15, 2023 |
As filed with the Securities and Exchange Commission on November 15, 2023 As filed with the Securities and Exchange Commission on November 15, 2023 Registration No. |
|
| November 15, 2023 |
Form of Debt Securities Warrant Agreement and Warrant Certificate Exhibit 4.5 Gamida Cell Ltd. and , As Warrant Agent Form of Debt Securities Warrant Agreement Dated As Of Gamida Cell Ltd. Form of Debt Securities Warrant Agreement This Debt Securities Warrant Agreement (this “Agreement”), dated as of [●], between Gamida Cell Ltd., a company organized under the laws of the State of Israel (the “Company”), and [●], a [corporation] [national banking association] or |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 15, 2023 |
Form of Ordinary Share Warrant Agreement and Warrant Certificate Exhibit 4.4 Gamida Cell Ltd. and , As Warrant Agent Form of Ordinary Share Warrant Agreement Dated As Of Gamida Cell Ltd. Form of Ordinary Share Warrant Agreement This Ordinary share Warrant Agreement (this “Agreement”), dated as of [●], between Gamida Cell Ltd., a company organized under the laws of the State of Israel (the “Company”), and [●], a [corporation] [national banking association] organ |
|
| November 14, 2023 |
Exhibit 10.1 COOPERATION AGREEMENT This Cooperation Agreement (this “Agreement”), effective as of August 11, 2023 (the “Effective Date”), is entered into by and among Gamida Cell Ltd., a public company formed under the laws of the State of Israel (the “Company” or “Gamida”), Jeremy Blank (the “New Director”) and Community Master Fund, LP, as a holder of Gamida’s ordinary shares, NIS 0.01 par value |
|
| November 14, 2023 |
Exhibit 99.1 Gamida Cell Reports Third Quarter 2023 Financial Results and Provides Company Update Company continues to advance launch, reports initial revenue from Omisirge® (omidubicel-onlv) Company to host conference call today at 8:30 a.m. ET BOSTON — NOVEMBER 14, 2023 — Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today reported fina |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 14, 2023 |
Amended and Restated Articles of Association of the Registrant, as currently in effect Exhibit 3.1 A LIMITED LIABILITY COMPANY AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF GAMIDA CELL LTD. As Adopted on October 30, 2018 and as last amended on, and effective as of October 19, 2023 Preliminary 1. Definitions; Interpretation. (a) In these Articles, the following terms (whether or not capitalized) shall bear the meanings set forth opposite them, respectively, unless the subject or co |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38716 GAMIDA CELL LTD. |
|
| November 8, 2023 |
GMDA / Gamida Cell Ltd / Community US Fund Management, Inc. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Gamida Cell Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M47364100 (CUSIP Number) Jeremy Blank c/o Community US Fund Management, Inc. 6446 Drexel Avenue Los Angeles, CA 90048 [(310) 430-4795][(646)-73 |
|
| October 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2023 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission Fil |
|
| October 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities and Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy S |
|
| October 2, 2023 |
EX-99.13 Exhibit 99.13 Joint Filing Agreement The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended. Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contai |
|
| October 2, 2023 |
GMDA / Gamida Cell Ltd / Ai Gamida Holdings Llc - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8)* Gamida Cell Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M47364100 (CUSIP Number) Alejandro Moreno Langhorne S. Perrow c/o Access Industries, Inc. 40 West 57th Street, 28th Floor New York, Ne |
|
| September 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities and Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy S |
|
| September 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2023 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission F |
|
| September 27, 2023 |
Exhibit 99.1 Media Contact: Dan Boyle Orangefiery [email protected] 1-818-209-1692 Investor Contact: Chuck Padala LifeSci Advisors [email protected] 1-646-627-8390 First Patient Receives Gamida Cell’s Omisirge™ (omidubicel-onlv) Omisirge is the only allogeneic stem cell therapy approved by the U.S. Food and Drug Administration (FDA) on the basis of a global randomized Phase 3 trial Rap |
|
| September 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| September 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| August 24, 2023 |
GMDA / Gamida Cell Ltd / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Gamida Cell Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M47364100 (CUSIP Number) August 15, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| August 21, 2023 |
GMDA / Gamida Cell Ltd / Community US Fund Management, Inc. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.)* Gamida Cell Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M47364100 (CUSIP Number) Jeremy Blank c/o Community US Fund Management, Inc. 6446 Drexel Avenue Los Angeles, CA 90048 [(310) 430-4795][(646)-734- |
|
| August 14, 2023 |
Exhibit 10.7 Execution Version AMENDED & RESTATED OPEN MARKET SALE AGREEMENTSM June 5, 2023 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Gamida Cell Ltd., a limited liability company organized under the laws of the State of Israel (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LL |
|
| August 14, 2023 |
Exhibit 99.1 Gamida Cell Reports Second Quarter and First Half 2023 Financial Results and Provides Company Update Strong start for Omisirge® (omidubicel-onlv) launch with significant payer coverage and number of transplant centers onboarded exceeding expectations Company continues to pursue strategic partnership to further support Omisirge launch Cash runway extended into Q2 2024; balance sheet st |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38716 GAMIDA CELL LTD. |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission File |
|
| August 14, 2023 |
Exhibit 10.5 May 19, 2023 Josh Patterson General Counsel & Chief Compliance Officer 116 Huntington Avenue, 7th Floor Boston, MA 02116 Re: Retention Bonus and Special Transaction Bonus Dear Josh: Retention Bonus In recognition of the critical role you have played with Gamida Cell Inc. (the “Company”) and will continue to play, we are pleased to offer you a special retention bonus of One Hundred Eig |
|
| August 14, 2023 |
Exhibit 10.3 May 19, 2023 Abigail Jenkins President & Chief Executive Officer 116 Huntington Avenue, 7th Floor Boston, MA 02116 Re: Special Transaction Bonus Dear Abbey: In recognition of the critical role you have played with Gamida Cell Inc. (the “Company”) and will continue to play in the Company’s (or its affiliate, Gamida Cell Ltd.’s) efforts to consummate either (x) an exclusive license agre |
|
| August 14, 2023 |
Exhibit 10.6 May 19, 2023 Ronit Simantov Medical and Chief Scientific Officer 116 Huntington Avenue, 7th Floor Boston, MA 02116 Re: Retention Bonus and Special Transaction Bonus Dear Ronit: Retention Bonus In recognition of the critical role you have played with Gamida Cell Inc. (the “Company”) and will continue to play, we are pleased to offer you a special retention bonus of One Hundred Ninety-T |
|
| August 14, 2023 |
Exhibit 10.4 May 19, 2023 Michele Korfin Chief Operating and Chief Commercial Officer 116 Huntington Avenue, 7th Floor Boston, MA 02116 Re: Retention Bonus and Special Transaction Bonus Dear Michele: Retention Bonus In recognition of the critical role you have played with Gamida Cell Inc. (the “Company”) and will continue to play, we are pleased to offer you a special retention bonus of One Hundre |
|
| August 14, 2023 |
Exhibit 10.2 AMENDED & RESTATED CONSULTING AGREEMENT THIS AMENDED & RESTATED CONSULTING AGREEMENT (the “Agreement”) is entered into as of May 22, 2023 by and between Gamida Cell Ltd., whose address is at 5 Nahum Heftsadie St., Jerusalem, Israel 9548401 (the “Company”), and Terry Coelho, an individual (the “Consultant”). WHEREAS, Company is in the business of research, development, and commercializ |
|
| May 26, 2023 |
GMDA / Gamida Cell Ltd / NOVARTIS PHARMA AG - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Gamida Cell Ltd. (Name of Issuer) Ordinary shares, par value NIS 0.01 per share (“Ordinary Shares”) (Title of Class of Securities) M47364100 (CUSIP Number) Karen L. Hale Chief Legal Officer Novartis AG Lichtstrasse 35 CH-4056 Basel Switzerland With a cop |
|
| May 26, 2023 |
Evidence of Signatory Authority EXHIBIT 4 EVIDENCE OF SIGNATORY AUTHORITY Excerpt from Commercial Register of Novartis Pharma AG Identification number Legal status Entry Cancelled 1 CHE-106. |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2023 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 22, 2023 |
Exhibit 99.1 Gamida Cell Appoints Terry Coelho as CFO Industry veteran Coelho brings more than 35 years of experience at emerging growth and global companies to role; Shai Lankry to depart June 2 BOSTON – May 22, 2023 - Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the appointment of Terry Coelho as chief financial officer |
|
| May 19, 2023 |
Amended and Restated Articles of Association of the Registrant, as currently in effect Exhibit 3.1 A LIMITED LIABILITY COMPANY - AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF GAMIDA CELL LTD. As Adopted on October 30, 2018 and as last amended on, and effective as of May 19, 2023 Preliminary 1. Definitions; Interpretation. (a) In these Articles, the following terms (whether or not capitalized) shall bear the meanings set forth opposite them, respectively, unless the subject or cont |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2023 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 16, 2023 |
As filed with the Securities and Exchange Commission on May 16, 2023 As filed with the Securities and Exchange Commission on May 16, 2023 Registration No. |
|
| May 16, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Gamida Cell Ltd. |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38716 GAMIDA CELL LTD. |
|
| May 15, 2023 |
Exhibit 99.1 Gamida Cell Reports First Quarter 2023 Financial Results and Provides Company Update Company reports positive feedback and continued progress on transplant center on-boarding and payer coverage around launch of Omisirge® (omidubicel-onlv), a new cell therapy for allogeneic stem cell transplant approved April 17 by the FDA Company successfully completed public offering, raising gross p |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| May 1, 2023 |
LIFE / Atyr Pharma Inc / Stonepine Capital Management, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Gamida Cell Ltd. (Name of Issuer) Ordinary Shares, NIS 0.01 par value (Title of Class of Securities) 002120202 (CUSIP Number) April 19, 20231 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| April 25, 2023 |
GMDA / Gamida Cell Ltd / Ai Gamida Holdings Llc - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* Gamida Cell Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M47364100 (CUSIP Number) Alejandro Moreno Langhorne S. Perrow c/o Access Industries, Inc. 40 West 57th Street, 28th Floor New York, Ne |
|
| April 25, 2023 |
EX-99.12 Exhibit 99.12 Joint Filing Agreement The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended. Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contai |
|
| April 24, 2023 |
GMDA / Gamida Cell Ltd / CVI Investments, Inc. - SC 13G Passive Investment CUSIP No: M47364100 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. )* Gamida Cell Ltd. (Name of Issuer) Ordinary shares, NIS 0.01 par value per share (Title of Class of Securities) M47364100 (CUSIP Number) |
|
| April 21, 2023 |
Exhibit 1.1 GAMIDA CELL LTD. 17,500,000 ORDINARY Shares Ordinary Warrants to purchase 17,500,000 ORDINARY Shares UNDERWRITING AGREEMENT April 19, 2023 Piper Sandler & Co. 800 Nicollet Mall Minneapolis, Minnesota 55402 As Representative of the Several Underwriters Ladies and Gentlemen: Gamida Cell Ltd., a corporation organized under the laws of the State of Israel (the “Company”), proposes, subject |
|
| April 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2023 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission File |
|
| April 21, 2023 |
Gamida Cell Announces Pricing of $23 Million Public Offering of Securities Exhibit 99.2 Gamida Cell Announces Pricing of $23 Million Public Offering of Securities BOSTON, Mass., April 19, 2023 – Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the pricing of an underwritten public offering of 17,500,000 ordinary shares and accompanying warrants to purchase 17,500,000 ordinary shares at a public offe |
|
| April 21, 2023 |
Gamida Cell Announces Launch of Public Offering of Securities Exhibit 99.1 Gamida Cell Announces Launch of Public Offering of Securities BOSTON, Mass., April 18, 2023 – Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the launch of a follow-on public offering of its ordinary shares and accompanying warrants to purchase its ordinary shares. In addition, Gamida Cell expects to grant the u |
|
| April 21, 2023 |
Exhibit 4.1 FORM GAMIDA CELL LTD. ORDINARY WARRANT TO PURCHASE ORDINARY SHARES Warrant No.: Warrant Shares: Initial Exercise Date: April 21, 2023 THIS ORDINARY WARRANT TO PURCHASE ORDINARY SHARES (this “Warrant”) certifies that, for value received, [•] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at a |
|
| April 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 20, 2023 |
Per Share And Accompanying Warrant Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-259472 PROSPECTUS SUPPLEMENT (to Prospectus dated April 1, 2022) Gamida Cell Ltd. 17,500,000 Ordinary Shares Ordinary Warrants to Purchase 17,500,000 Ordinary Shares We are offering (i) 17,500,000 ordinary shares and (ii) Ordinary Warrants to purchase an aggregate of 17,500,000 ordinary shares, each an Ordinary Warrant and collectivel |
|
| April 19, 2023 |
SUBJECT TO COMPLETION, DATED APRIL 19, 2023 Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-259472 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not offers to sell these securities, and we are not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitted. SUBJ |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2023 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission File |
|
| April 17, 2023 |
Exhibit 99.1 Gamida Cell’s Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval Omisirge is approved by the FDA as a new donor source for allogeneic stem cell transplant Global, randomized Phase 3 clinical trial showed faster neutrophil recovery and reduced bacterial and fungal infections as compared to standard cord blood Omisirge may increase access to stem cell transplant, |
|
| April 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 4, 2023 |
EX-99.11 Exhibit 99.11 Joint Filing Agreement The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1) promulgated under the Securities and Exchange Act of 1934, as amended. Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person co |
|
| April 4, 2023 |
GMDA / Gamida Cell Ltd / Ai Gamida Holdings Llc - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Gamida Cell Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M47364100 (CUSIP Number) Alejandro Moreno Langhorne S. Perrow c/o Access Industries, Inc. 40 West 57th Street, 28th Floor New York, Ne |
|
| March 31, 2023 |
Amended and Restated Articles of Association of Gamida Cell Ltd. Exhibit 3.1 A LIMITED LIABILITY COMPANY AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF GAMIDA CELL LTD. As Adopted on October 30, 2018, as amended on November 17, 2021 and as last amended on, and effective as of July 27, 2022 Preliminary 1. Definitions; Interpretation. (a) In these Articles, the following terms (whether or not capitalized) shall bear the meanings set forth opposite them, respecti |
|
| March 31, 2023 |
Exhibit 10.22 AMENDMENT TO EMPLOYMENT AGREEMENT This AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into as of July 26, 2022, by and between Gamida Cell, Inc., a Delaware corporation (the “Company”), and Ronit Simantov (the “Employee”) (individually, each a “Party” and collectively, the “Parties”). WHEREAS, Employee is employed by the Company and performs services for the |
|
| March 31, 2023 |
Exhibit 4.1 DESCRIPTION OF SHARE CAPITAL The following descriptions of our share capital and provisions of our amended and restated articles of association are summaries and do not purport to be complete. For a complete description you should refer to our amended and restated articles of incorporation which are included as an exhibit to our Annual Report on Form 10-K, and to the applicable provisi |
|
| March 31, 2023 |
Exhibit 10.24 AMENDMENT TO EMPLOYMENT AGREEMENT This AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into as of July 15, 2022, by and between Gamida Cell, Inc., a Delaware corporation (the “Company”), and JOSHUA PATTERSON (the “Employee”) (individually, each a “Party” and collectively, the “Parties”). WHEREAS, Employee is employed by the Company and performs services for t |
|
| March 31, 2023 |
Employment Agreement, dated July 15, 2021, by and between Gamida Cell, Inc. and Josh Patterson Exhibit 10.23 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”), dated as of July 15, 2021 (the “Effective Date”) is by and between GAMIDA CELL, INC., a Delaware Corporation (the “Company”), and JOSHUA PATTERSON (the “Employee”) (individually, each a “Party” and collectively, the “Parties”). WHEREAS, in recognition of the Employee’s experience and abilities, the Company desires to |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-38716 GAMIDA CELL LTD. (Exact |
|
| March 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2023 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission File |
|
| March 27, 2023 |
Exhibit 99.1 Gamida Cell Reports Full Year 2022 Financial Results and Provides Company Update Company reports on productive interactions with FDA and preparations for launch of omidubicel, if approved, in advance of May 1 PDUFA date Company outlines strategic restructuring, plans to prioritize omidubicel launch and reduce operating expenses to extend cash runway Company to explore strategic option |
|
| March 20, 2023 |
Exhibit 99.1 Investor and Media Contact: Dan Boyle Orangefiery [email protected] 1-818-209-1692 Gamida Cell Announces Changes to Board of Directors Shawn Cline Tomasello to become Chairwoman, succeeding Chairman Robert I. Blum, who is resigning; Company focuses on upcoming regulatory milestone and commercialization Directors Dr. Naama Halevi-Davidov and Dr. Anat Cohen-Dayag also stepping down |
|
| March 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2023 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission File |
|
| March 3, 2023 |
Evidence of Signatory Authority EXHIBIT 4 EVIDENCE OF SIGNATORY AUTHORITY Excerpt from Commercial Register of Novartis Pharma AG Identification number Legal status Entry Cancelled 1 CHE-106. |
|
| March 3, 2023 |
GMDA / Gamida Cell Ltd / NOVARTIS PHARMA AG - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Gamida Cell Ltd. (Name of Issuer) Ordinary shares, par value NIS 0.01 per share (“Ordinary Shares”) (Title of Class of Securities) M47364100 (CUSIP Number) Karen Hale Chief Legal Officer Novartis AG Lichtstrasse 35 CH-4056 Basel Switzerland With a copy t |
|
| February 14, 2023 |
GMDA / Gamida Cell Ltd / Community US Fund Management, Inc. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 10, 2023 |
GMDA / Gamida Cell Ltd / HIGHBRIDGE CAPITAL MANAGEMENT LLC - GAMIDA CELL LTD Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Gamida Cell Ltd. (Name of Issuer) Ordinary shares, par value NIS 0.01 per share (Title of Class of Securities) M47364100 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant |
|
| January 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as Permitted by Ru |
|
| January 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2023 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission Fil |
|
| January 20, 2023 |
Gamida Cell Ltd. Up to 14,868,724 Ordinary Shares offered by Selling Shareholder Filed Pursuant to Rule 424(b)(3) Registration No. 333-269181 PROSPECTUS Gamida Cell Ltd. Up to 14,868,724 Ordinary Shares offered by Selling Shareholder The selling shareholder identified in this prospectus may offer from time to time up to 14,868,724 ordinary shares of Gamida Cell Ltd., or the Company, issuable upon the exchange of, or in satisfaction of, any principal amortization payment, inter |
|
| January 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2023 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission Fil |
|
| January 18, 2023 |
CORRESP 1 filename1.htm January 18, 2023 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Cindy Polynice Re: Gamida Cell Ltd. Registration Statement on Form S-3 Filed January 11, 2023 File No. 333-269181 Acceleration Request Requested Date: January 20, 2023 Requested Time: 4:00 p.m. Eastern Time Ladies and Gentlemen: |
|
| January 11, 2023 |
As filed with the Securities and Exchange Commission on January 11, 2023 As filed with the Securities and Exchange Commission on January 11, 2023 Registration No. |
|
| January 11, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Gamida Cell Ltd. |
|
| January 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission File |
|
| December 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| December 12, 2022 |
Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of December 12, 2022, by and between Gamida Cell Ltd., a limited liability company formed under the laws of the State of Israel (the “Company”), Gamida Cell Inc., a Delaware corporation and wholly-owned subsidiary of the Company (the “Issuer”), and each buyer identified in t |
|
| December 12, 2022 |
Exhibit 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may be amended, restated, modified, or supplemented from time to time, this “Agreement”) dated as of December 12, 2022 (the “Effective Date”) among Wilmington Savings Fund Society, FSB, as administrative agent (in such capacity, together with its successors and assigns in such capacity, “Administrative Agent”) a |
|
| December 12, 2022 |
Gamida Cell Announces Closing of $25 Million Financing with Highbridge Exhibit 99.1 Gamida Cell Announces Closing of $25 Million Financing with Highbridge Boston, Mass. – December 12, 2022 – Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, announced the closing of a senior secured convertible term loan of $25 million with certain funds manage |
|
| December 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2022 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission Fi |
|
| December 12, 2022 |
Form of 7.5% First Lien Secured Note due 2024 Exhibit 10.2 FORM OF FIRST LIEN SECURED NOTE THE SECURITIES REPRESENTED BY THIS NOTE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE FOREIGN OR STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS |
|
| November 21, 2022 |
Exhibit 99.1 Gamida Cell Provides Regulatory Update on Omidubicel Recent company submission in response to FDA request extends PDUFA date by three months Boston, Mass. – November 21, 2022 – Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematological and solid cancers and other serious diseases, today provided an update on recent inte |
|
| November 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2022 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 15, 2022 |
Exhibit 99.10 Joint Filing Agreement The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accura |
|
| November 15, 2022 |
GMDA / Gamida Cell Ltd / Ai Gamida Holdings Llc - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Gamida Cell Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M47364100 (CUSIP Number) Alejandro Moreno Langhorne S. Perrow c/o Access Industries, Inc. 40 West 57th Street, 28th Floor New York, New York 10 |
|
| November 14, 2022 |
Exhibit 99.1 Gamida Cell Reports Third Quarter 2022 Financial Results and Provides Company Update - Commercial launch preparations underway ahead of January 30, 2023 PDUFA target action date – - New data presented across multiple medical meetings to support the potential of omidubicel as an advanced cell therapy, including long term follow-up data from the Phase 3 study, a real-world analysis of d |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38716 GAMIDA CELL LTD. |
|
| September 30, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2022 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission F |
|
| September 30, 2022 |
Gamida Cell Announces Pricing of Approximately $20 Million Public Offering of Ordinary Shares Exhibit 99.1 Gamida Cell Announces Pricing of Approximately $20 Million Public Offering of Ordinary Shares BOSTON, Mass., September 28, 2022 ? Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced the pricing of a follow-on public offering of 12,905,000 of its o |
|
| September 30, 2022 |
Exhibit 1.1 GAMIDA CELL LTD. 12,905,000 Shares ORDINARY SHARES, NOMINAL VALUE NIS 0.01 PER SHARE UNDERWRITING AGREEMENT September 27, 2022 Piper Sandler & Co. 800 Nicollet Mall Minneapolis, Minnesota 55402 As Representative of the Several Underwriters Ladies and Gentlemen: Gamida Cell Ltd., a limited liability company organized under the laws of the State of Israel (the ?Company?), proposes, subje |
|
| September 29, 2022 |
Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-259472 PROSPECTUS SUPPLEMENT (to Prospectus dated April 1, 2022) Gamida Cell Ltd. 12,905,000 Ordinary Shares All of the 12,905,000 ordinary shares in this offering are being sold by the company. Our ordinary shares are traded on The Nasdaq Global Market, or Nasdaq, under the symbol ?GMDA.? On September 27, 2022, the last reported sale |
|
| September 27, 2022 |
SUBJECT TO COMPLETION, DATED SEPTEMBER 27, 2022 Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-259472 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not offers to sell these securities, and we are not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitted. SUBJ |
|
| September 27, 2022 |
Gamida Cell Announces Launch of Public Offering of Ordinary Shares Exhibit 99.1 Gamida Cell Announces Launch of Public Offering of Ordinary Shares BOSTON, Mass., September 27, 2022 ? Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced the launch of a follow-on public offering of its ordinary shares. In addition, Gamida Cell e |
|
| September 27, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2022 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission F |
|
| September 19, 2022 |
Employment Agreement, dated September 18, 2022, by and between Gamida Cell Inc. and Abigail Jenkins Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this ?Agreement?), dated as of September 18, 2022 (the ?Effective Date?) is by and between GAMIDA CELL INC., a Delaware Corporation (the ?Company?), and ABIGAIL JENKINS (the ?Employee?) (each a ?Party? and collectively, the ?Parties?). WHEREAS, in recognition of the Employee?s experience and abilities, the Company desires to assure itsel |
|
| September 19, 2022 |
Exhibit 99.1 Gamida Cell Appoints Abigail L. Jenkins as President and Chief Executive Officer, Bringing Broad Leadership Experience in Commercializing Innovative Therapies ? Julian Adams, Ph.D., to Retire and Remain on the Board as Planned Succession Boston, Mass. ? September 19, 2022 ? Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients |
|
| September 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2022 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission F |
|
| August 15, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission File |
|
| August 15, 2022 |
Exhibit 99.1 Gamida Cell Reports Second Quarter 2022 Financial Results and Provides Company Update - Received FDA acceptance of BLA for omidubicel with Priority Review; PDUFA target action date set for January 30, 2023 - - Dosed first patient in company-sponsored Phase 1/2 study of cryopreserved formulation of GDA-201 for the treatment of follicular and diffuse large B-cell lymphomas - - Finished |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38716 GAMIDA CELL LTD. |
|
| August 10, 2022 |
Exhibit 99.1 Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201 -The company-sponsored Phase 1/2 study is evaluating a cryopreserved, readily available formulation of GDA-201 for the treatment of follicular and diffuse large B cell lymphomas - Boston, Mass. ? August 10, 2022 ? Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the de |
|
| August 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events, 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2022 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission File |
|
| August 1, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events, 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2022 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission File |
|
| August 1, 2022 |
Exhibit 99.1 Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review - If approved, omidubicel will be the first allogeneic advanced stem cell therapy donor source for patients with blood cancers in need of a stem cell transplant - - PDUFA target action date is January 30, 2023 - - Company to host conference call on BLA acceptance and commercial op |
|
| July 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2022 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission File N |
|
| July 13, 2022 |
DEFR14A 1 ea162828-defr14agamidacell.htm AMENDMENT NO. 1 TO FORM DEF14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Co |
|
| June 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| June 14, 2022 |
Gamida Cell Ltd. Up to 6,334,455 Ordinary Shares offered by Selling Shareholders Filed Pursuant to Rule 424(b)(7) Registration No. 333-253720 PROSPECTUS Gamida Cell Ltd. Up to 6,334,455 Ordinary Shares offered by Selling Shareholders The selling shareholders identified in this prospectus may offer from time to time up to 6,334,455 ordinary shares of Gamida Cell Ltd. issuable upon the exchange of $75,000,000 of 5.875% exchangeable senior notes due 2026 (the ?notes?) issued by G |
|
| June 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission File Nu |
|
| June 10, 2022 |
Exhibit 99.9 Joint Filing Agreement The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accurac |
|
| June 10, 2022 |
GMDA / Gamida Cell Ltd / Ai Gamida Holdings Llc - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Gamida Cell Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M47364100 (CUSIP Number) Alejandro Moreno Langhorne S. Perrow c/o Access Industries, Inc. 40 West 57th Street, 28th Floor New York, New York 10 |
|
| June 10, 2022 |
GMDA / Gamida Cell Ltd / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2*) GAMIDA CELL LTD. (Name of Issuer) COMMON STOCK (Title of Class of Securities) M47364100 (CUSIP Number) May 31, 2022 (Date of Event Which Requires Filing of this Statement |
|
| June 10, 2022 |
PRE 14A 1 pre14a0622gamidacell.htm PRELIMINARY PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential |
|
| June 10, 2022 |
Exhibit 99.1 Gamida Cell Appoints Ivan M. Borrello, M.D., Expert in Immuno-Oncology, Cell Therapies, and Bone Marrow Transplant to Board of Directors Boston, Mass. ? June 10, 2022 ? Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announces the appointment of Ivan M. Bor |
|
| June 2, 2022 |
Exhibit 99.1 Gamida Cell Completes Rolling Biologics License Application Submission to the FDA for Omidubicel - Omidubicel is a first-in-class, advanced NAM-enabled stem cell therapy candidate being evaluated as the first potential allogeneic advanced cell therapy donor source for patients with blood cancers in need of a transplant ? - Omidubicel has Orphan Drug Designation and Breakthrough Therap |
|
| June 2, 2022 |
Financial Statements and Exhibits, Other Events, Regulation FD Disclosure, 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2022 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission File Nu |
|
| June 1, 2022 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) GAMIDA CELL LTD. |
|
| June 1, 2022 |
As filed with the Securities and Exchange Commission on June 1, 2022 As filed with the Securities and Exchange Commission on June 1, 2022 Registration No. |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38716 GAMIDA CELL LTD. |
|
| May 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 10, 2022 |
Exhibit 99.1 Gamida Cell Reports First Quarter 2022 Financial Results and Provides Company Update - On track for full BLA submission of omidubicel in the second quarter of 2022 - - Planning to open sites for enrollment in second quarter of 2022 for Phase 1/2 study of GDA-201 in patients with follicular and diffuse large B-cell lymphomas - - Presented new preclinical data supporting potential of NA |
|
| April 26, 2022 |
Exhibit 99.1 Gamida Cell Announces FDA Clearance of IND and Removal of Clinical Hold for NK Cell Therapy Candidate GDA-201 Company advancing plans to begin Phase 1/2 study in patients with follicular and diffuse large B-cell lymphomas BOSTON-(BUSINESS WIRE) ? April 26, 2022- Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic a |
|
| April 26, 2022 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2022 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission File |
|
| March 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A/A Amendment No. 1 FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Gamida Cell Ltd. (Exact name of registrant as specified in its charter) Israel Not Applicable (State or other jurisdiction of incorporation or organization) (IRS Employer Identifi |
|
| March 25, 2022 |
As filed with the Securities and Exchange Commission on March 25, 2022 As filed with the Securities and Exchange Commission on March 25, 2022 Registration No. |
|
| March 25, 2022 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) GAMIDA CELL LTD. |
|
| March 24, 2022 |
Employment agreement, dated April 30, 2017, by and between Gamida Cell Inc. and Ronit Simantov Exhibit 10.18 April 30, 2017 Ronit Simantov 500 East 85th Street Apt 7H New York, NY 10028 Dear Ronit, On behalf of Gamida Cell Inc. (the ?Company?), I am pleased to offer you the position of Chief Medical Officer (?CMO?). The Company?s offer, as set forth in this letter agreement, is contingent upon your presentation to the Company of proof of your authorization to work in the United States and t |
|
| March 24, 2022 |
Employment agreement, dated July 20, 2020, by and between Gamida Cell Inc. and Michele Korfin Exhibit 10.17 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this ?Agreement?), dated as of July 20, 2020 (the ?Effective Date?) is by and between GAMIDA CELL, INC., a Delaware Corporation (the ?Company?), and MICHELE KORFIN (the ?Employee?) (individually, each a ?Party? and collectively, the ?Parties?). WHEREAS, in recognition of the Employee?s experience and abilities, the Company desires to as |
|
| March 24, 2022 |
Form of Indemnification Agreement Exhibit 10.1 indemnification agreement THIS INDEMNIFICATION AGREEMENT (the ?Agreement?), dated as of , is entered into by and between Gamida Cell Ltd., an Israeli company whose address is 5 Nahum Heftsadie Street Givaat Shaul, Jerusalem 91340, Israel (the ?Company?), and the undersigned Director or Officer of the Company whose name appears on the signature page hereto (the ?Indemnitee?). WHEREAS, |
|
| March 24, 2022 |
Employment agreement, dated December 15, 2021, by and between Gamida Cell Inc. and Shai Lankry Exhibit 10.16 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this ?Agreement?), dated as of December 15, 2021 (the ?Effective Date?) is by and between GAMIDA CELL, INC., a Delaware Corporation (the ?Company?), and SHAI LANKRY (the ?Employee?) (individually, each a ?Party? and collectively, the ?Parties?). WHEREAS, until immediately prior to the Effective Date, the Employee served in the capacity |
|
| March 24, 2022 |
Employment agreement, dated November 20, 2017, by and between Gamida Cell Inc. and Dr. Julian Adams Exhibit 10.15 November 20, 2017 Dr. Julian Adams 673 Boylston St. Boston, MA 02116 Dear Julian, On behalf of Gamida Cell Inc. (the ?Company?), I am pleased to offer you the position of Chief Executive Officer. The Company?s offer, as set forth in this letter agreement, is contingent upon your presentation to the Company of proof of your authorization to work in the United States and the approval o |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-38716 GAMIDA CELL LTD. (Exact |
|
| March 24, 2022 |
Exhibit 4.3 DESCRIPTION OF SHARE CAPITAL The following descriptions of our share capital and provisions of our amended and restated articles of association are summaries and do not purport to be complete. For a complete description you should refer to our amended and restated articles of incorporation which are included as an exhibit to our Annual Report on Form 10-K, and to the applicable provisi |
|
| March 24, 2022 |
2017 Share Incentive Plan, as amended Exhibit 10.6 Gamida Cell Ltd. 2017 Share Incentive Plan (as amended and restated July 1, 2020) Unless otherwise defined, terms used herein shall have the meaning ascribed to them in Section 2 hereof. 1. PURPOSE; TYPES OF AWARDS; CONSTRUCTION. 1.1. Purpose. The purpose of this 2017 Share Incentive Plan (as amended, this ?Plan?) is to afford an incentive to Service Providers of Gamida Cell Ltd., an |
|
| March 24, 2022 |
Exhibit 10.19 DATED 07 January 2020 GAMIDA CELL LIMITED (1) and UPPAL HEALTHCARE LIMITED (2) CONSULTANCY AGREEMENT DATE OF AGREEMENT 2020 PARTIES (1) GAMIDA CELL LIMITED, a company registered in Israel whose registered office is at 5th Nahum Hefzadi st. Jerusalem, Israel (?We? or the ?Company?) (2) UPPAL HEALTHCARE LIMITED (Company Number 08321724) whose registered office is at Kingswood House, 35 |
|
| March 24, 2022 |
Amended and Restated Articles of Association of Gamida Cell Ltd. Exhibit 3.1 A LIMITED LIABILITY COMPANY - AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF GAMIDA CELL LTD. As Adopted on October 30, 2018 as amended on, and effective as of, November 17, 2021 Preliminary 1. Definitions; Interpretation. (a) In these Articles, the following terms (whether or not capitalized) shall bear the meanings set forth opposite them, respectively, unless the subject or context |
|
| March 15, 2022 |
Exhibit 99.1 Gamida Cell Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update - Initiated rolling BLA submission for omidubicel in the first quarter of 2022 with full BLA submission on track for first half of 2022 - - Finished fourth quarter of 2021 with approximately $96 million in cash; sufficient cash to fund the company?s operations into mid-2023 - - Company |
|
| March 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2022 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission File |
|
| February 14, 2022 |
SC 13G/A 1 gmdaa121422.htm CONSONANCE CAPITAL MANAGEMENT LP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* GAMIDA CELL LTD (Name of Issuer) Ordinary Shares, Nominal Value NIS 0.01 per share (Title of Class of Securities) M47364100 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing |
|
| February 14, 2022 |
GMDA / Gamida Cell Ltd / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ?.11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1*) GAMIDA CELL LTD. (Name of Issuer) COMMON STOCK (Title of Class of Securities) M47364100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Stat |
|
| February 11, 2022 |
GMDA / Gamida Cell Ltd / HIGHBRIDGE CAPITAL MANAGEMENT LLC - GAMIDA CELL LTD. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Gamida Cell Ltd. (Name of Issuer) Ordinary shares, par value NIS 0.01 per share (Title of Class of Securities) M47364100 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant |
|
| February 9, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2022 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction (Commission File Number) (IRS Emp |
|
| February 9, 2022 |
Exhibit 99.1 Gamida Cell Initiates Rolling Submission of Biologics License Application for Omidubicel On track to complete the BLA submission in the first half of 2022 BOSTON ? February 9, 2022 ? Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, today announced that it has initiated the Biologics License Application (BLA) ro |
|
| February 8, 2022 |
Exhibit 99.9 Joint Filing Agreement The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accurac |
|
| February 8, 2022 |
GMDA / Gamida Cell Ltd / Ai Gamida Holdings Llc - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Gamida Cell Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M47364100 (CUSIP Number) Alejandro Moreno c/o Access Industries, Inc. 40 West 57th Street, 28th Floor New York, New York 10019 (212) 247-6400 w |
|
| January 31, 2022 |
Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2022 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission Fil |
|
| January 31, 2022 |
Gamida Cell Provides Key Program Updates and 2022 Financial Guidance Exhibit 99.1 Gamida Cell Provides Key Program Updates and 2022 Financial Guidance ? Initiating rolling BLA submission for omidubicel in the first quarter of 2022 with full BLA submission on track for first half of 2022 ? Evaluating strategic alternatives for commercialization of omidubicel, including potential licensing or partnering ? Reducing operating expense to extend cash runway to fund activ |
|
| January 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2022 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission Fil |
|
| January 31, 2022 |
Exhibit 99.1 Gamida Cell Announces Appointment of Anat Cohen-Dayag and Naama Halevi-Davidov to its Board of Directors Boston, Mass. ? January 31, 2022 ? Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, today announced the addition of Anat Cohen-Dayag, Ph.D., and Naama Halevi-Davidov, Ph.D., to its Board of Directors as Clas |
|
| January 19, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2022 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or other jurisdiction of incorporation) (Commission Fil |
|
| January 19, 2022 |
Gamida Cell Provides Update on Omidubicel BLA Submission Exhibit 99.1 Gamida Cell Provides Update on Omidubicel BLA Submission ? Planning to initiate rolling BLA submission for omidubicel following positive Type B meeting with FDA ? Full BLA submission on track for first half of 2022 BOSTON ? January 19, 2022 ? Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, announced that follo |
|
| January 3, 2022 |
8-K 1 ea153113-8kgamidacellltd.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2022 Gamida Cell Ltd. (Exact name of registrant as specified in its Charter) Israel 001-38716 Not Applicable (State or oth |
|
| November 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of November 2021 Commission File Number 001-38716 GAMIDA CELL LTD. (Translation of registrant?s name into English) 5 Nahum Heftsadie Street Givaat Shaul, Jerusalem 91340 Israel (Address of princip |
|
| November 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of November 2021 Commission File Number 001-38716 GAMIDA CELL LTD. (Translation of registrant?s name into English) 5 Nahum Heftsadie Street Givaat Shaul, Jerusalem 91340 Israel (Address of princip |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of November 2021 Commission File Number 001-38716 GAMIDA CELL LTD. (Translation of registrant?s name into English) 5 Nahum Heftsadie Street Givaat Shaul, Jerusalem 91340 Israel (Address of princip |
|
| November 15, 2021 |
Exhibit 99.2 Gamida Cell ltd. AND ITS SUBSIDIARY INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2021 U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page Interim Consolidated Statements of Financial Position 3 ? 4 Interim Consolidated Statements of Comprehensive Loss 5 Interim Consolidated Statements of Changes in Equity 6 ? 8 Interim Consolidated Statements of Cash Flows 9 ? 10 Notes to |
|
| November 15, 2021 |
Gamida Cell Reports Third Quarter 2021 Financial Results and Provides Company Update Exhibit 99.1 Gamida Cell Reports Third Quarter 2021 Financial Results and Provides Company Update ? New data being presented at American Society of Hematology (ASH) Annual Meeting demonstrating GDA-201 overall survival rate of 78% at two years with a median duration of response of 16 months and long-term clinical benefit of omidubicel with long-lasting hematopoietic recovery ? Finished third quart |
|
| November 12, 2021 |
Gamida Cell Provides Update on Pre-BLA Meeting with FDA for Omidubicel Exhibit 99.1 Gamida Cell Provides Update on Pre-BLA Meeting with FDA for Omidubicel - Gamida Cell conducted pre-BLA meeting for omidubicel with FDA - FDA requested revised analysis of manufacturing data generated at Gamida Cell?s commercial manufacturing facility - BLA submission expected in the first half of 2022 Boston, Mass. ? November 11, 2021 ? Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cel |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of November 2021 Commission File Number 001-38716 GAMIDA CELL LTD. (Translation of registrant?s name into English) 5 Nahum Heftsadie Street Givaat Shaul, Jerusalem 91340 Israel (Address of princip |
|
| October 26, 2021 |
Exhibit 99.1 Gamida Cell to Present NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline and Update on GDA-201 at Today?s Virtual R&D Day ? Company recently filed an IND application for GDA-201; FDA placed the application on Clinical Hold pending modifications to donor eligibility procedures and sterility assay qualification ? Today?s presentations to highlight expanded NAM-enabled NK cell t |
|
| October 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of October 2021 Commission File Number 001-38716 GAMIDA CELL LTD. (Translation of registrant?s name into English) 5 Nahum Heftsadie Street Givaat Shaul, Jerusalem 91340 Israel (Address of principa |
|
| October 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of October 2021 Commission File Number 001-38716 GAMIDA CELL LTD. (Translation of registrant?s name into English) 5 Nahum Heftsadie Street Givaat Shaul, Jerusalem 91340 Israel (Address of principa |
|
| October 12, 2021 |
Proxy card for use in connection with the Meeting. Exhibit 99.2 |
|
| October 12, 2021 |
5 Nahum Heftsadie Street, Givaat Shaul, Jerusalem 91340 Israel Exhibit 99.1 5 Nahum Heftsadie Street, Givaat Shaul, Jerusalem 91340 Israel October 12, 2021 Dear Shareholder, You are cordially invited to attend an annual general meeting of the shareholders (the ?Meeting?) of Gamida Cell Ltd. (the ?Company?), to be held on November 17, 2021, beginning at 5:00 pm, Israel time (10:00 a.m. ET), at 12 Leshem Street, Kiryat Gat, 8258412, Israel. A live webcast of th |
|
| September 17, 2021 |
September 17, 2021 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Margaret Schwartz Re: Gamida Cell Ltd. Registration Statement on Form F-3 Filed September 13, 2021 File No. 333-259472 Acceleration Request Requested Date: September 21, 2021 Requested Time: 4:00 p.m. Eastern Time Ladies and Gentlemen: In accordance w |
|
| September 13, 2021 |
Form of Indenture between the Registrant and one or more trustees to be named Exhibit 4.3 GAMIDA CELL LTD., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20 Debt Securities article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate 8 Section 2.03 Denominations: Provi |
|
| September 13, 2021 |
As filed with the Securities and Exchange Commission on September 10, 2021 As filed with the Securities and Exchange Commission on September 10, 2021 Registration No. |
|
| September 13, 2021 |
Open Market Sale Agreement dated September 10, 2021, by and among Gamida Cell Ltd. and Jefferies LLC Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM September 10, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Gamida Cell Ltd., a limited liability company organized under the laws of the State of Israel (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or princip |
|
| August 13, 2021 |
Gamida Cell Reports Second Quarter 2021 Financial Results and Provides Company Update Exhibit 99.1 Gamida Cell Reports Second Quarter 2021 Financial Results and Provides Company Update ? BLA submission for omidubicel, a potentially life-saving treatment for patients with blood cancers in need of stem cell transplant, expected in fourth quarter of 2021 ? Commercial readiness activities underway to support potential launch in 2022 ? Phase 1/2 clinical trial of GDA-201 in patients wit |
|
| August 13, 2021 |
Exhibit 99.2 Gamida Cell ltd. AND ITS SUBSIDIARY INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2021 U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page Interim Consolidated Statements of Financial Position 1 Interim Consolidated Statements of Comprehensive Loss 3 Interim Consolidated Statements of Changes in Equity 4 Interim Consolidated Statements of Cash Flows 7 Notes to Interim Consolidat |
|
| August 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of August 2021 Commission File Number 001-38716 GAMIDA CELL LTD. (Translation of registrant?s name into English) 5 Nahum Heftsadie Street Givaat Shaul, Jerusalem 91340 Israel (Address of principal |
|
| August 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of August 2021 Commission File Number 001-38716 GAMIDA CELL LTD. (Translation of registrant?s name into English) 5 Nahum Heftsadie Street Givaat Shaul, Jerusalem 91340 Israel (Address of principal |
|
| June 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of June 2021 Commission File Number 001-38716 GAMIDA CELL LTD. (Translation of registrant?s name into English) 5 Nahum Heftsadie Street Givaat Shaul, Jerusalem 91340 Israel (Address of principal e |
|
| June 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of June 2021 Commission File Number 001-38716 GAMIDA CELL LTD. (Translation of registrant?s name into English) Nahum Heftsadie Street Givaat Shaul, Jerusalem 91340 Israel (Address of principal exe |
|
| June 7, 2021 |
Exhibit 99.1 Gamida Cell Announces Appointment of Senior Vice President, Global Operations and Manufacturing and Provides Commercial Manufacturing Update Boston, Mass. ? June 7, 2021 ? Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced the appointment of Vladimir Melnikov as senior vice president, globa |
|
| May 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of May 2021 Commission File Number 001-38716 GAMIDA CELL LTD. (Translation of registrant?s name into English) 5 Nahum Heftsadie Street Givaat Shaul, Jerusalem 91340 Israel (Address of principal ex |
|
| May 11, 2021 |
Exhibit 99.1 Gamida Cell Reports First Quarter 2021 Financial Results and Provides Company Update ? BLA submission for omidubicel, a potentially life-saving treatment for patients with blood cancers in need of stem cell transplant, expected in fourth quarter of 2021 ? Pre-commercial and manufacturing activities underway to support potential launch of omidubicel in 2022 ? Phase 1/2 clinical trial o |
|
| May 11, 2021 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of May 2021 Commission File Number 001-38716 GAMIDA CELL LTD. (Translation of registrant?s name into English) 5 Nahum Heftsadie Street Givaat Shaul, Jerusalem 91340 Israel (Address of principal ex |
|
| March 11, 2021 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F for the year ended December 31, 2020 (the ?Report?) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the ?E |
|
| March 11, 2021 |
- AMENDMENT NO. 1 TO FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 FORM 20-F ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIE |
|
| March 11, 2021 |
Gamida Cell Ltd. Up to 6,334,455 Ordinary Shares offered by Selling Shareholders Filed pursuant to Rule 424(b)(7) Registration Statement No. 333-253720 PROSPECTUS Gamida Cell Ltd. Up to 6,334,455 Ordinary Shares offered by Selling Shareholders The selling shareholders identified in this prospectus may offer from time to time up to 6,334,455 ordinary shares Gamida Cell Ltd. issuable upon the exchange of $75,000,000 of 5.875% exchangeable senior notes due 2026 (the “notes”) issu |
|
| March 11, 2021 |
Exhibit 15.2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the reference to our firm under the caption “Experts” in the Registration Statement (Form F-3 No. 333-253720) and related Prospectus of Gamida Cell Ltd. and its subsidiary (the “Company”) for the registration of its ordinary shares and to the incorporation by reference therein of our report dated March 9, 2021, wit |
|
| March 11, 2021 |
Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statement on Form S-8 (File No. 333-238115) pertaining to the 2017 Share Incentive Plan and the Registration Statement on Form F-3 (File No. 333-234701) of Gamida Cell and its subsidiary (the “Company”), of our report dated March 9, 2021, with respect to the consol |
|
| March 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Gamida Cell Ltd. (Name of Issuer) Ordinary shares, par value NIS 0.01 per share (“Ordinary Shares”) (Title of Class of Securities) M47364100 (CUSIP Number) Shannon Thyme Klinger Chief Legal Officer Novartis AG Lichtstrasse 35 CH-4056 Basel Switzerland Wi |
|
| March 11, 2021 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F for the year ended December 31, 2020 (the ?Report?) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the ?E |
|
| March 11, 2021 |
Exhibit 12.1 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Julian Adams, certify that: 1. I have reviewed this annual report on Form 20-F of Gamida Cell Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a ma |
|
| March 11, 2021 |
Exhibit 12.2 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Shai Lankry, certify that: 1. I have reviewed this annual report on Form 20-F of Gamida Cell Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a mat |
|
| March 9, 2021 |
March 9, 2021 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 4546 Washington, D.C. 20549 Attn: Chris Edwards Re: Gamida Cell Ltd. Registration Statement on Form F-3 Filed March 1, 2021 File No. 333-253720 Acceleration Request Requested Date: March 10, 2021 Requested Time: 4:00 p.m. Eastern Time Ladies and Gentlemen: In accordance with |
